1-(4-((1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)oxy)phenyl)-5-(methylsulfonyl)indoline | 1379530-16-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(4-((1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)oxy)phenyl)-5-(methylsulfonyl)indoline
• 英文别名: 1-[4-[1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl]oxyphenyl]-5-methylsulfonyl-2,3-dihydroindole
• CAS: 1379530-16-1
• 化学式: C₂₆H₃₀N₄O₃S
• 分子量: 478.615
• InChiKey: RRLNQGPGFOQXLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] BICYCLIC GPR119 MODULATORS<br/>[FR] MODULATEURS DE GPR119 BICYCLIQUES
  申请人：LUPIN LTD

  公开号：WO2012069917A1

  公开（公告）日：2012-05-31

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR1 19 receptor by using either alone or in combinations of Formula (I).

  本发明涉及一种化合物（I）的公式，该化合物对治疗、预防和/或管理与调节GPR119受体活性相关的疾病、紊乱、综合征或病况有用。该发明还涉及制备这些化合物的方法、其药物组成物。此外，该发明还涉及利用单独或以公式（I）的组合物治疗、预防和/或管理与调节GPR119受体相关的疾病、紊乱、综合征或病况的方法。
• BICYCLIC GPR119 MODULATORS
  申请人：Thotapally Rajesh

  公开号：US20130245000A1

  公开（公告）日：2013-09-19

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).

  本发明涉及化合物(I)的使用，该化合物对于治疗、预防和/或管理与GPR119受体活性调节相关的疾病、紊乱、综合症或病况是有用的。本发明还涉及该化合物的制备过程、制药组合物。本发明还涉及使用化合物(I)单独或与其他化合物联合治疗、预防和/或管理与GPR119受体活性调节相关的疾病、紊乱、综合症或病况的方法。
• US9000175B2
  申请人：——

  公开号：US9000175B2

  公开（公告）日：2015-04-07